ALLOGENE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.89 USD | +1.23% |
|
-16.71% | -9.97% |
Chart calendar Allogene Therapeutics, Inc.
57aa67866.6MCgEtSHqM54t5sfGGOLmi7AMLstqw25nRHzCcSgs9A.urDlSKXX3qtI3fRSIDz87WXzAN9l6SDMpUajeY_31oW4ouUmp-DgqADY1g~81ab12490d22a4f3298af0a3d8f3081d
Upcoming events on Allogene Therapeutics, Inc.
Past events on Allogene Therapeutics, Inc.
| 15/04/2024 20:00 | CG Horizons in Oncology Virtual Conference |
| 14/03/2024 21:00 | Q4 2023 Earnings Call |
| 14/03/2024 20:05 | Q4 2023 Earnings Release |
| 06/03/2024 14:10 | TD Cowen Health Care Conference |
| 14/02/2024 17:00 | Oppenheimer Healthcare Life Sciences Conference |
| 07/02/2024 16:30 | Guggenheim Healthcare Talks Biotechnology Conference |
| 18/01/2024 20:30 | B. Riley Securities Oncology Conference |
| 10/01/2024 16:15 | JPMorgan Healthcare Conference |
| 04/01/2024 22:00 | Business Update Call |
| 12/12/2023 02:00 | American Society of Hematology Meeting - Abstract Number : 4832 |
| 10/12/2023 01:30 | American Society of Hematology Meeting - Abstract Number : 2095 |
| 06/12/2023 16:30 | JMP Securities Hematology and Oncology Summit |
| 15/11/2023 13:30 | Jefferies London Healthcare Conference |
| 04/11/2023 16:00 | Society for Immunotherapy of Cancer Meeting - Abstract Number: 302 |
| 03/11/2023 16:00 | Society for Immunotherapy of Cancer Meeting - Abstract Number: 283 |
| 03/11/2023 16:00 | Society for Immunotherapy of Cancer Meeting - Abstract Number: 279 |
| 03/11/2023 15:30 | TD Cowen Fall Oncology Innovation Summit |
| 02/11/2023 21:00 | Q3 2023 Earnings Call |
| 02/11/2023 20:02 | Q3 2023 Earnings Release |
| 26/09/2023 16:00 | Jefferies Cell & Genetic Medicine Summit |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 38,5 38,4 0.31% | 0,24 0,19 25.77% | 0,10 0,13 -28.76% | 0,04 |
|
EBITDA Million USD | Released Forecast Spread | -198 -204 3.02% | -251 -250 -0.51% | -245 -258 4.75% | -321 -325 1.17% | -314 -294 -6.61% | -258 |
|
EBIT Million USD | Released Forecast Spread | -202 -210 3.93% | -258 -263 1.77% | -256 -266 3.99% | -335 -341 1.68% | -328 -321 -2.09% | -287 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -185 -195 5.37% | -250 -257 2.69% | -257 -265 3% | -333 -340 2.12% | -327 -313 -4.44% | -283 |
|
Net income Million USD | Released Forecast Spread | -185 -195 5.47% | -250 -257 2.62% | -257 -265 3.01% | -333 -339 1.97% | -327 -312 -4.73% | -283 |
|
EPS USD | Released Forecast Spread | -1,83 -1,94 5.84% | -2,08 -2,14 2.71% | -1,89 -1,97 3.82% | -2,32 -2,37 2.18% | -2,09 -2,01 -3.96% | -1,68 |
| Announcement Date | 27/02/20 | 25/02/21 | 23/02/22 | 28/02/23 | 14/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,05 0,01 614.29% | 0,06 0,01 754.34% | 0,09 0,02 444.65% | 0,05 0,01 289.82% | 0,05 0,06 -26.8% | 0,05 0,01 677.28% | 0,04 0,02 141.1% | 0,04 0,01 347.92% | 0,02 0,02 -6.25% | 0,01 | 0,01 | 0,01 | 0,01 | 0,01 |
|
EBITDA Million USD | Released Forecast Spread | -69,7 -83,1 16.14% | -76,3 -82,0 6.95% | -72,9 -84,0 13.19% | -78,6 -86,0 8.57% | -93,3 -94,6 1.41% | -95,6 -90,0 -6.18% | -76,9 -80,9 4.97% | -59,4 -76,1 21.95% | -81,6 -58,2 -40.23% | -68,4 | -67,3 | -66,8 | -66,4 | -71,6 |
|
EBIT Million USD | Released Forecast Spread | -73,9 -83,6 11.62% | -80,0 -83,2 3.82% | -76,6 -87,4 12.32% | -82,5 -95,1 13.26% | -96,4 -102 5.59% | -99,1 -88,8 -11.51% | -80,5 -86,5 6.91% | -63,0 -81,1 22.3% | -85,1 -78,4 -8.58% | -69,6 | -69,0 | -69,6 | -72,2 | -74,6 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -74,9 -82,4 9.13% | -79,9 -82,5 3.25% | -74,8 -85,9 12.92% | -83,1 -93,0 10.61% | -94,8 -102 7.04% | -98,7 -88,0 -12.12% | -78,0 -86,2 9.55% | -61,3 -79,1 22.47% | -85,8 -75,2 -14.02% | -68,1 | -68,2 | -68,8 | -71,1 | -73,9 |
|
Net income Million USD | Released Forecast Spread | -74,9 -82,4 9.18% | -79,9 -82,4 3.15% | -74,8 -86,0 13.09% | -83,1 -92,5 10.15% | -94,8 -101 5.9% | -98,7 -88,9 -10.99% | -78,0 -86,3 9.6% | -61,3 -78,9 22.29% | -85,8 -74,4 -15.33% | -68,0 | -68,2 | -68,9 | -71,1 | -73,9 |
|
EPS USD | Released Forecast Spread | -0,54 -0,60 9.56% | -0,56 -0,58 3.19% | -0,52 -0,60 13.99% | -0,58 -0,64 9.38% | -0,66 -0,70 5.65% | -0,68 -0,62 -9.47% | -0,53 -0,59 10.58% | -0,37 -0,52 28.86% | -0,51 -0,45 -12.39% | -0,41 | -0,40 | -0,40 | -0,41 | -0,41 |
| Announcement Date | 23/02/22 | 04/05/22 | 09/08/22 | 02/11/22 | 28/02/23 | 03/05/23 | 02/08/23 | 02/11/23 | 14/03/24 | - | - | - | - | - |
More events
Past sector events for Allogene Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ALLO Stock
- Calendar Allogene Therapeutics, Inc.
